Opioids: Drivers and Anomalous Prescribing Patterns

Presented by: Steve Barry, Neeraj Tadur, Derek Wong

12/4/2018

Opioids: What are they?


- Pain reliever drugs
- Physician prescribed and also illegal street drugs
- Varying kinds, varying strengths
- Some opioids have high potential for dependence and overdose
- "Man-made opioid epidemic"








Why is this important?



America's Overdose Epidemic In Perspective

Drug-induced deaths per million of the population*



Data Used

- Original Source: Centers for Medicare and Medicaid Services (CMS)
- Sampled from Kaggle
 - https://www.kaggle.com/apryor6/us-opiate-prescriptions/home
- Prescriber Level (25,000 x 256)
 - 25,000 licensed medical professionals
 - By Gender, Specialty, and Credentials
 - o 250 common non-opioid and opioid drugs what they are prescribing, and how often
- State Level (50 x 4)
 - Aggregate population and overdose death rate statistics
- Drug Level (113 x 2)
 - Drug names, Generic

Data Used

| | State | Population | Deaths | Abbrev |
|---|------------|------------|--------|--------|
| 0 | Alabama | 4,833,722 | 723 | AL |
| 1 | Alaska | 735,132 | 124 | AK |
| 2 | Arizona | 6,626,624 | 1,211 | AZ |
| 3 | Arkansas | 2,959,373 | 356 | AR |
| 4 | California | 38,332,521 | 4,521 | CA |

| | Drug Name | Generic Name |
|---|--------------------------------|--------------------------------|
| 0 | ABSTRAL | FENTANYL CITRATE |
| 1 | ACETAMINOPHEN-CODEINE | ACETAMINOPHEN WITH CODEINE |
| 2 | ACTIQ | FENTANYL CITRATE |
| 3 | ASCOMP WITH CODEINE | CODEINE/BUTALBITAL/ASA/CAFFEIN |
| 4 | ASPIRIN-CAFFEINE-DIHYDROCODEIN | DIHYDROCODEINE/ASPIRIN/CAFFEIN |

| | NPI | Gender | State | Credentials | Specialty | ABILIFY | ACETAMINOPHEN.CODEINE | ACYCLOVIR | ADVAIR.DISKUS | AGGRENOX | | VERAPA |
|---|------------|--------|-------|-------------|---------------------|---------|-----------------------|-----------|---------------|----------|-----|--------|
| 0 | 1710982582 | М | TX | DDS | Dentist | 0 | 0 | 0 | 0 | 0 | | |
| 1 | 1245278100 | F | AL | MD | General Surgery | 0 | 0 | 0 | 0 | 0 | 2.2 | |
| 2 | 1427182161 | F | NY | M.D. | General Practice | 0 | 0 | 0 | 0 | 0 | *** | |
| 3 | 1669567541 | M | AZ | MD | Internal Medicine | 0 | 43 | 0 | 0 | 0 | | |
| 4 | 1679650949 | М | NV | M.D. | Hematology/Oncology | 0 | 0 | 0 | 0 | 0 | | |

Sections Today

- 1. Exploration of the Data
- 2. Making Predictions
- 3. Identifying Prescriber Outliers through Cluster Analysis
- 4. Wrap-Up


Making Predictions

- Exploring the data
 - Geographic
 - Deaths from Opioids by State
 - Prescribers of Opioids by State
 - Demographic
 - Rates of Prescribers by Gender

Predicting Opioid Prescribers

- Using Categorical Supervised Learning
- Preparing the data
- Feature Selection
- Which models worked the best
- Using different features and filters

Overdoses vs Prescribers By State




Prescibers by State (relative to population) -120-110

Overdose Rate by State per Capita

Opioid Prescriber Rate by State per Capita

- Prescriber rates by state show little variance, while overdose rates have higher variance
- There appears to be some weak regional correlation between prescribers rates and ODs
 - Our data is limited in that we have only 25,000 prescribers and 256 drugs we are looking at

Prescribers by Gender



Opioid Prescriber Rate

| | Gender | Total.Prescriber | Opioid.Prescriber | Percent.Prescibers |
|---|--------|------------------|-------------------|--------------------|
| 0 | F | 9426 | 5135 | 54.477 |
| 1 | M | 15574 | 9553 | 61.339 |

- Male prescribers using this dataset do prescribe opioids at a higher rate than Female prescribers
 The type of practitioner might greatly influence this data
- Our data is limited in that we have only 25,000 prescribers and 256 drugs we are looking at

Making Predictions with Supervised Learning

Preparing and Choosing the data:

- Converting categorical fields to numeric
- Dropping uninformative data (NPI, Credentials)
- Tried predictions without all drugs (speciality/state)
- Predictions with all drugs
- Predictions without opioid drugs
- Predictions by specialty w/out opioid drugs

Categorical methods attempted:

- Logistic Regression
- K Nearest Neighbours
- Classification Tree
- Random Forest
- Bagging and Boosting

| NPI Gender State Credentials Specialty ABII IFY | int64 object object object object int64 | |
|--|--|---------|
| ACETAMINOPHEN. | | int64 |
| ACYCLOVIR | int64 | 1110-1 |
| ADVAIR.DISKUS | int64 | 1 |
| AGGRENOX | int64 | |
| ALENDRONATE.SO | DIUM | int64 |
| ALLOPURINOL | int64 | |
| ALPRAZOLAM | int64 | |
| AMIODARONE.HCL | | t64 |
| AMITRIPTYLINE.HC | | t64 |
| AMLODIPINE.BESY | _, | int64 |
| AMLODIPINE.BESY | LATE.BENAZE | PRIL |
| int64 | | |
| AMOXICILLIN | int64 | |
| AMOX.TR.POTASSI | UM.CLAVULA | NATE |
| int64 | | |
| AMPHETAMINE.SAL | _T.COMBO | |
| int64 | | |
| ATENOLOL | int64 | |
| ATORVASTATIN.CA | | int64 |
| AVODART | int64 | |
| AZITHROMYCIN BACLOFEN | int64 | 4 |
| BD.ULTRA.FINE.PE | | int64 |
| BENAZEPRIL.HCL | int6 | |
| BENAZEPRIL. TICL BENICAR | int64 | 04 |
| BENICAR BENICAR.HCT | int64 | |
| BENZTROPINE.MES | | int64 |
| DENZINOI IINE.IVIE |) LAIL | 11110-1 |

TIMOLOL.MALEATE int64 TIZANIDINE HCI int64 TOLTERODINE.TARTRATE.ER int64 TOPIRAMATE int64 TOPROL XI int64 TORSEMIDE int64 int64 TRAMADOL.HCL TRAVATAN 7 int64 TRAZODONE.HCL int64 TRIAMCINOLONE.ACETONIDE TRIAMTERENE.HYDROCHLOROTHIAZID int64 VALACYCI OVIR int64 VALSARTAN int64 VALSARTAN.HYDROCHLOROTHIAZIDE VENI AFAXINE HCI int64 VENI AFAXINE HCL FR int64 VENTOLIN.HFA int64 VFRAPAMII FR int64 VESICARE int64 **VOLTAREN** int64 VYTORIN int64 WARFARIN SODIUM int64 XARFI TO int64 7FTIA int64 ZIPRASIDONE HCI int64 ZOLPIDEM.TARTRATE int64 Opioid.Prescriber int64 Gender1 int64 int64 State1 int64 Specialtv1 Length: 259, dtvpe; object

Model Performance using all drug columns

Model Performance:

Logistic Regression: 0.912


K Nearest Neighbours: 0.858

Classification Tree: 0.888


Random Forest: 0.911


DT with Bagging: 0.815

DT with Boosting: 0.96





Cross Validation Plots/Scores





Logistic Regression: 0.912





Random Forest: 0.911

Model Performance without Opioid Drug Columns

Model Performance:

Logistic Regression : 0.759


K Nearest Neighbours: 0.778

Classification Tree: 0.779

Random Forest: 0.823

DT with Bagging: 0.636

DT with Boosting: 0.89



Opioids Dropped:

- 1 MORPHINE.SLFATE.ER
- 2 FENTANYL
- 3 OXYCODONE.HCL
- 4 OXYCONTIN
- **5 MORPHINE. SULFATE**
- 6 OXYCODONE.ACETAMINOPHEN
- 7 HYDROMORPHONE.HCL
- 8 METHADONE.HCL
- 9 HYDROCODONE.ACETAMINOPHEN
- 10 TRAMADOL.HCL
- 11 ACETAMINOPHEN.CODEINE

Predicting Prescribers by Specialty (Internal Medicine)

Model Performance:

Logistic Regression : 0.847


K Nearest Neighbours : 0.812

Classification Tree: 0.805

Random Forest: 0.831

DT with Bagging: 0.743

DT with Boosting: 0.89



Notes:

- State1 informs this model the most of all features
- Remaining significant features are non-opioid drugs that may have "associative" relation with prescribed opioids

Why did Boosting using Decision Tree outperform?

Bagging vs Boosting

These are ensemble methods which combine several "weaker" models into a "stronger" ensemble.

Bagged models that are trained independently on data that is bootstrapped from the input data. Best used with limited data. We have 25K rows of prescribers.

Boosting creates a strong learner by iteratively adding "weak" learners and adjusting the weight of each weak learner to focus on misclassified examples. Worked best with our data.

When to use Boosting

- · When predictors are categorical
- When the time taken to train a model is less of a concern

Source: https://quantdare.com/what-is-the-difference-between-bagging-and-boosting/


Identifying Prescriber Outliers through Cluster Analysis

 Motivation: Identify prescribers that are prescribing a different drug profile compared to their peers aka "outliers"

- Controlling Factors:
 - Specialty
 - State
 - Opioid Prescriber Flag

Prescriber Outliers - Approach

- We will use unsupervised clustering to create clusters of prescribers based on their drugs prescribed
- We expect to see a dominant cluster with most of the physicians, but also a smaller subset of physicians which we will consider the outliers



Prescriber Outliers - Scaling (TF-IDF Principles)

But first...


Term Frequency x Inverse Document Frequency

- Commonly used in document classification, is meant to normalize the length of the documents and give more weight when documents share uncommon key words
- 1) Normalize every prescriber by the total number of drugs prescribed. In other words, state each drug as % of total drugs prescribed
- 2) Give varying weights to each of the drugs, where uncommon drugs receive more weight and common drugs receive less weight

Prescriber Outliers - Techniques Considered/Used

Clustering


- K-Means
- Hierarchical Clustering
- Density-based Clustering (DBSCAN)
- Dimensionality Reduction / Visualization
 - T-distributed Stochastic Neighbor Embedding (t-SNE)
 - Principal Component Analysis (PCA)



DBSCAN Parameter Eps: Silhouette Score is a score from -1 to +1, with +1 being the strongest evidence of distinct clusters.


Prescriber Outliers - PCA

- Plotting data on PCA basis allows visualization of underlying data differences
- Filters
 - Internal Medicine
 - New York
 - Opioid Prescribers




Prescriber Outliers - PCA with Cluster Results (NY)

- Plotting data on PCA basis allows visualization of underlying data differences
- Filters
 - Internal Medicine
 - New York
 - Opioid Prescribers
- Red represents "Outlier" cluster label



Prescriber Outliers - PCA with Cluster Results (PA)

- Plotting data on PCA basis allows visualization of underlying data differences
- Filters
 - Family Practice
 - Pennsylvania
 - Opioid Prescribers
- Red represents "Outlier" cluster label



Prescriber Outliers - Drug Patterns by Cluster

- Results shown for NY
- Prescribers in the Outlier group prescribed 4x as many opioids as those in the Inlier group (NY, PA)

Differences - Opioids Only

| Index | Inliers % | Outliers % | Difference | Is Opioid? |
|---------------------------|-----------|------------|------------|------------|
| OXYCODONE.HCL | 0.2 | 4.7 | 4.5 | Yes |
| OXYCODONE.ACETAMINOPHEN | 0.4 | 3.7 | 3.3 | Yes |
| MORPHINE.SULFATE.ER | 0 | 0.8 | 0.8 | Yes |
| OXYCONTIN | 0 | 0.7 | 0.7 | Yes |
| HYDROMORPHONE.HCL | 0 | 0.5 | 0.5 | Yes |
| MORPHINE.SULFATE | 0 | 0.3 | 0.3 | Yes |
| ACETAMINOPHEN.CODEINE | 0.2 | 0.5 | 0.3 | Yes |
| METHADONE.HCL | 0 | 0.2 | 0.2 | Yes |
| FENTANYL | 0.2 | 0.3 | 0.1 | Yes |
| HYDROCODONE.ACETAMINOPHEN | 0.7 | 0.9 | 0.1 | Yes |
| TRAMADOL.HCL | 0.5 | 0.3 | -0.3 | Yes |

Differences - All Drugs

| Index | Inliers % | Outliers % | Difference | Is Opioid? |
|-------------------------------|-----------|------------|------------|------------|
| OXYCODONE.HCL | 0.2 | 4.7 | 4.5 | Yes |
| OXYCODONE.ACETAMINOPHEN | 0.4 | 3.7 | 3.3 | Yes |
| PREDNISONE | 0.6 | 3 | 2.4 | No |
| LEVOFLOXACIN | 0.2 | 2.5 | 2.2 | No |
| ZOLPIDEM.TARTRATE | 1.1 | 2.7 | 1.6 | No |
| DOXYCYCLINE.HYCLATE | 0.1 | 1.6 | 1.5 | No |
| CEFUROXIME | 0 | 1.4 | 1.4 | No |
| SULFAMETHOXAZOLE.TRIMETHOPRIM | 0.2 | 1.5 | 1.3 | No |
| AZITHROMYCIN | 0.6 | 1.7 | 1.1 | No |
| IBUPROFEN | 0.4 | 1.4 | 1.1 | No |
| PROAIR.HFA | 0.8 | 1.8 | 1.1 | No |
| ACYCLOVIR | 0 | 1.1 | 1.1 | No |
| ALPRAZOLAM | 0.6 | 1.6 | 1 | No |
| NAPROXEN | 0.3 | 1.3 | 1 | No |
| LAMOTRIGINE | 0 | 1.1 | 1 | No |
| VOLTAREN | 0.3 | 1 | 0.8 | No |
| MORPHINE.SULFATE.ER | 0 | 0.8 | 0.8 | Yes |
| CIPROFLOXACIN.HCL | 0.4 | 1.2 | 0.8 | No |
| OXYCONTIN | 0 | 0.7 | 0.7 | Yes |

Prescriber Outliers - Drug Patterns by Cluster

- Results shown for PA
- Prescribers in the Outlier group prescribed 4x as many opioids as those in the Inlier group (NY, PA)

Differences - Opioids Only


| Index | Inliers % | Outliers % | Difference | Is Opioid? |
|---------------------------|-----------|------------|------------|------------|
| OXYCODONE.HCL | 0.5 | 11.7 | 11.2 | Yes |
| OXYCODONE.ACETAMINOPHEN | 0.6 | 4.3 | 3.7 | Yes |
| HYDROCODONE.ACETAMINOPHEN | 1.8 | 4.8 | 3 | Yes |
| METHADONE.HCL | 0 | 0.8 | 0.7 | Yes |
| OXYCONTIN | 0.2 | 0.6 | 0.4 | Yes |
| MORPHINE.SULFATE.ER | 0.2 | 0.5 | 0.3 | Yes |
| HYDROMORPHONE.HCL | 0 | 0 | -0 | Yes |
| MORPHINE.SULFATE | 0.1 | 0 | -0.1 | Yes |
| FENTANYL | 0.3 | 0.2 | -0.1 | Yes |
| ACETAMINOPHEN.CODEINE | 0.1 | 0 | -0.1 | Yes |
| TRAMADOL.HCL | 1.2 | 0.8 | -0.5 | Yes |

Differences - All Drugs

| Index | Inliers % | Outliers % | Difference | Is Opioid? |
|--------------------------------|-----------|------------|------------|------------|
| OXYCODONE.HCL | 0.5 | 11.7 | 11.2 | Yes |
| OXYCODONE.ACETAMINOPHEN | 0.6 | 4.3 | 3.7 | Yes |
| HYDROCODONE.ACETAMINOPHEN | 1.8 | 4.8 | 3 | Yes |
| ALPRAZOLAM | 1.2 | 3.5 | 2.3 | No |
| AZITHROMYCIN | 0.6 | 2.3 | 1.8 | No |
| PREDNISONE | 0.7 | 2.5 | 1.8 | No |
| CEPHALEXIN | 0.2 | 1.9 | 1.7 | No |
| DIAZEPAM | 0.2 | 1.3 | 1.1 | No |
| DOXYCYCLINE.HYCLATE | 0.1 | 1.1 | 1 | No |
| CIPROFLOXACIN.HCL | 0.4 | 1.3 | 0.9 | No |
| LISINOPRIL.HYDROCHLOROTHIAZIDE | 0.8 | 1.7 | 0.9 | No |
| IBUPROFEN | 0.4 | 1.2 | 0.9 | No |
| SULFAMETHOXAZOLE.TRIMETHOPRIM | 0.2 | 1 | 0.8 | No |
| AMOX.TR.POTASSIUM.CLAVULANATE | 0.2 | 1 | 0.8 | No |
| LEVOFLOXACIN | 0.2 | 0.9 | 0.7 | No |
| METHADONE.HCL | 0 | 0.8 | 0.7 | Yes |

Methods Considered But Not Used for Prediction

- Dimensionality Reduction(PCA)
 - Interpretability would be lost since dimensions get compressed
 - Wanted to see the importance of Individual features and their combinations



Methods Considered But Not Used for Prediction Cont.

- SVM scores less than other models such as Boosting
 - Accuracy score: 0.73
- Why didn't we use regression
 - Our data was categorical and not continuous
- Association Rule Mining or Graph / Social Network Analysis
 - Our data was not at the transaction level

Future Work

- Continue exploration on geographic drivers outside of data, including state regulatory and medical fee schedule differences
- Augment analysis with patient level data
 - Transaction data
 - Drug or medical history associations
 - Illicit drug data and consumption
- Determine if Outlier drug prescription patterns are indeed anomalous by engaging domain experts from medical field
- Analyze prescriber behavior relative to their peers on a transactional level

Opioid epidemic tracking Metrics(NC)


North Carolina Opioid action plan has been developed to combat the opioid crisis


Metrics:

- Treatment and Recovery
- Reduce Oversupply of Prescription Opioids
- 3. Increase access to Naloxone
- 4. Reduce flow of Illicit Drugs

| Metrics | Current Data | 2021 Trend/Goal |
|---|--------------------------------------|---------------------------------------|
| OVERALL | | |
| Number of unintentional opioid-related deaths (ICD10) | 1,194 (2016, provisional) | 20% reduction in expected 2021 number |
| Rate of opioid ED visits (all intents) | 38.2 per 100,000 residents (2015) | 20% reduction in expected 2021 rate |
| Reduce oversupply of prescription opioids | | |
| Rate of multiple provider episodes for prescription opioids (times patients received opioids from ≥ 5 prescribers dispensed at ≥ 5 pharmacies in a six-month period), per 100,000 residents | 27.3 per 100,000 residents (2016) | Decreasing trend |
| Total number of opioid pills dispensed | 555,916,512 (2016) | Decreasing trend |
| Percent of patients receiving more than an average daily dose of >90 MME of opioid analgesics, per quarter | 12.3% (Q1 2017) | Decreasing trend |
| Percent of prescription days any patient had at least one opioid AND at least one benzodiazepine prescription on the same day, per quarter | 21.1% (Q1 2017) | Decreasing trend |
| Reduce Diversion/Flow of Illicit Drugs | | |
| Percent of opioid deaths involving heroin or fentanyl/fentanyl analogues | 58.4% (2016, provisional) | |
| Number of acute Hepatitis C cases | 182 (2016, provisional) | Decreasing trend |
| Increase Access to Naloxone | | |
| Number of EMS naloxone administrations | 13,069 (2016, provisional) | |
| Number of community naloxone reversals | 3,616 (2016) | Increasing trend |
| Treatment and Recovery | | |
| Number of buprenorphine prescriptions dispensed | 467,243 (2016) | Increasing trend |
| Number of uninsured individuals with an opioid use disorder served by treatment programs | 12,248 (SFY16) | Increasing trend |
| Number of certified peer support specialists (CPSS) across NC | 2,383 (2016) | Increasing trend |

Metric Plots(NC)





Metrics Evaluation

- Analyze number of unintentional deaths and ED Visits by observing diagnosis codes and patient level transactional data
- Compute average rate of multiple provider episodes for prescription Opioids
- Analyze the diversion and flow of illicit drugs-Percent of opioid deaths involving heroin and fentanyl analogues by observing ICD - 10 codes
- Number of uninsured individuals and Medicaid beneficiaries with an opioid use disorder served by treatment programs